Description du projet
Une nouvelle technologie de détection pour la surveillance des patients souffrant d’insuffisance cardiaque
L’insuffisance cardiaque chronique est une maladie implacable qui touche des millions de personnes et met à rude épreuve les ressources de santé. Avec un taux de mortalité à 5 ans de 50 % et des coûts annuels qui dépassent les 30 000 dollars par patient, il s’agit d’un dilemme de soins de santé pressant. La vie des patients est accablée par des hospitalisations fréquentes et un taux de mortalité élevé. Dans ce contexte, le projet FORESEE financé par le CEI se propose de développer des dispositifs de microdétection implantables. La clé de cette approche transformatrice réside dans le développement de dispositifs implantables ultraminces et flexibles, dépourvus de composants ou de batteries encombrants. Alimentés sans fil, les microcapteurs promettent de révolutionner la surveillance de l’insuffisance cardiaque chronique et d’améliorer les soins aux patients. L’objectif de FORESEE est de faire passer cette plateforme de détection innovante du concept à la réalité.
Objectif
We have developed and in-human validated a new generation of implantable microstimulators for neuroprosthetics, accomplishing very thin (< 1 mm) and flexible devices with an unprecedented level of miniaturization as they lack batteries and bulky components. Our microstimulators are powered by an external system using an innovative wireless power transfer method that uses the human body as an electrical conductor of innocuous high frequency currents. While developing the microstimulators, we realized that this technology could also be used to create minimally invasive implants capable of sensing relevant biomedical parameters for remote patient monitoring (RPM). Our technology has the potential to revolutionize RPM, as it allows to combine different sensing capabilities in a single device and to create a network of implants for multi-site sensing. After analysing several opportunities, we decided to focus the applicability of our sensing platform to chronic heart failure (HF) monitoring. Chronic HF is a long-term, persistent condition in which the heart is not able to efficiently pump blood to the body, causing symptoms such as limited physical activity and swelling. With time, the patient decompensates, leading to repeated costly hospitalizations with an annual cost of caring of US$30,000 per patient in US, and a 5-years mortality rate of 50%. RPM using implanted sensors is an emerging clinical reality for HF patients, as it optimizes medical management and treatment, improving their quality of life and outcomes. The objective of FORESEE is to bring the implantable microsensing platform for RPM of HF patients from TRL3 up to completion of TRL5, and to develop a successful business strategy to ensure its future market access, benefiting almost 10.5 million HF patients in EU and US that are candidates for RPM. The technological and business activities developed by our team with strong scientific and business expertise will ensure tech-to-market transition.
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Régime de financement
HORIZON-EIC - HORIZON EIC GrantsCoordinateur
08002 Barcelona
Espagne